601818:SSEChina Everbright Bank Co., Ltd. Class A Analysis
Data as of 2026-03-17 - not real-time
CN¥3.34
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
China Everbright Bank trades at a **trailing PE of 5.57**, dramatically below the industry average of 16.63, and a **price‑to‑book of 0.40**, indicating a deep value discount. The stock offers an attractive **5.74% dividend yield** with a modest **payout ratio of 31.5%**, suggesting the dividend is well‑covered by earnings and cash flow. Technically, the price sits at 3.34 CNY, just below the calculated resistance of 3.36 CNY and above the support of 3.18 CNY, while the 20‑day SMA (3.28) remains under the 50‑day SMA (3.35), signalling a short‑term bearish bias. However, the MACD histogram is positive and the MACD line sits above its signal, offering a *bullish* micro‑trend, and the RSI of 56 points to neutral momentum. Volatility over the past 30 days is moderate at 14.2% and beta is effectively zero, implying low market‑wide price sensitivity.
Given the strong cash position, low leverage (debt‑to‑equity reported as 0), and solid profitability margins (operating margin 62%, profit margin 44%), the fundamentals are resilient despite a **max drawdown of nearly 28%** historically. The combination of deep valuation discounts, sustainable dividend, and defensive risk profile makes the stock a compelling **value‑oriented** play, though investors should stay mindful of sector‑specific regulatory and geographic headwinds in China.
Given the strong cash position, low leverage (debt‑to‑equity reported as 0), and solid profitability margins (operating margin 62%, profit margin 44%), the fundamentals are resilient despite a **max drawdown of nearly 28%** historically. The combination of deep valuation discounts, sustainable dividend, and defensive risk profile makes the stock a compelling **value‑oriented** play, though investors should stay mindful of sector‑specific regulatory and geographic headwinds in China.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with SMA20 < SMA50 indicating short‑term bearish bias
- Bullish MACD histogram providing a counter‑trend signal
- Neutral RSI and stable volume suggest limited upside in the near term
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation discount (PE 5.57 vs industry 16.63)
- High dividend yield with low payout ratio supporting cash returns
- Low beta and moderate volatility reducing market‑wide risk
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable earnings and strong operating margins
- Robust cash position relative to debt, providing balance‑sheet resilience
- Undervalued price relative to book and earnings, offering upside potential as market sentiment normalizes
Key Metrics & Analysis
Financial Health
Revenue Growth-10.00%
Profit Margin43.68%
P/E Ratio5.6
ROE6.84%
ROA0.58%
P/B Ratio0.4
Op. Cash FlowCN¥25.6B
Industry P/E16.6
Technical Analysis
TrendBearish
RSI56.1
SupportCN¥3.18
ResistanceCN¥3.36
MA 20CN¥3.28
MA 50CN¥3.35
MA 200CN¥3.69
MACDBullish
VolumeStable
Fear & Greed Index81.32
Valuation
GradeUndervalued
TypeValue
Dividend Yield5.74%
Risk Assessment
Beta-0.00
Volatility14.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.